IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections. As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.
Most significant clincal trials of 2024
Dec 23, 2024 · There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure prophylaxis (PrEP) drugs, 2024 has been a busy year in the clinical trial space. While many drugs have hailed ...
Pfizer reports data from prostate cancer combination therapy trial
Oct 11, 2024 · Participants were divided into two cohorts: an all-comers group and those with homologous recombination repair (HRR) gene mutations. Radiographic progression-free survival (rPFS) was the trial’s primary endpoint while secondary endpoints comprised OS, objective response rate (ORR), duration of response (DOR) and prostate-specific antigen (PSA) response.
BlueRock reports positive data from Parkinson’s cell therapy trial
Sep 30, 2024 · The primary endpoint of safety and tolerability was assessed at 12 months, alongside evaluations of cell survival and motor effects. The results have shown that bemdaneprocel’s safety profile at 24 months was in line with prior data, indicating good tolerance and no adverse events directly related to the therapy.
Gilead’s lenacapavir shows promise in HIV prevention trial
Nov 28, 2024 · Gilead Sciences has announced the outcomes from the randomised Phase III PURPOSE 2 trial evaluating lenacapavir for human immunodeficiency virus (HIV) prevention.. The trial demonstrated a 96% reduction in HIV infections compared to background incidence, with lenacapavir showing strong efficacy and tolerability.
AHA 2024: Zerlasiran shows promising Phase II results for elevated ...
Nov 19, 2024 · Dr. Steven Nissen, MD chairman and chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of Medicine, reported that subcutaneous injections of 300mg or 450mg of zerlasiran, administered every 16 or 24 weeks, reduced time-averaged Lp(a) levels by 80% to 85% over a follow-up period of 36 to 60 weeks.
ESMO 2024: Moderna’s mRNA solid tumour vaccine shows early …
Sep 13, 2024 · Moderna’s mRNA cancer vaccine for solid tumours shows early signs of promise in interim data from a Phase I study.. The messenger ribonucleic acid (mRNA) specialist announced the vaccine has shown early signs of an immune response against cancer, with the shot triggering cancer-killing cells.
Novo Nordisk reports positive data from semaglutide trial for MASH
Nov 4, 2024 · Novo Nordisk reports positive data from part one of semaglutide trial for MASH. ESSENCE is a double-blinded, 240-week study that involves 1,200 adults with MASH and stage two or three liver fibrosis.
2024: record year for AI trials - Clinical Trials Arena
Dec 23, 2024 · Another significant application of AI in clinical trials is the management of trial data. This is becoming increasingly important since the amount of data points being collected is increasing exponentially as trial complexity evolves.
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy …
Oct 4, 2024 · The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran (del-desiran).. In 2022, the US regulatory agency placed a partial hold after a report of a serious adverse event in a newly enrolled patient in the Phase I/II MARINA trial (NCT05027269), which evaluated del-desiran in patients myotonic dystrophy ...